CareDx, Inc (CDNA) Balance Sheet

Equity grew from $303.1M to $467.5M over the same stretch, largely reflecting cash generation and a $121.7M goodwill step-up in 2026Q3 that warrants scrutiny of what was acquired. The improvement appears driven by operating and financing inflows rather than asset revaluation, though the reported figures alone cannot confirm the underlying sources. Investors should monitor whether the cash build is sustained once working capital normalizes.

Debt has trended only modestly, ranging from $24.5M to $31.4M across the ten quarters, which suggests the company has not relied on borrowing to fund growth. Low leverage reduces the pressure on future cash flows to service obligations. The absence of material debt means balance sheet risk is driven more by earnings volatility than by financing structure.

The decline in current ratio from 4.58 to 2.31 over a single quarter appears linked to rising current liabilities alongside the drawdown of short-term cash positions, which warrants further investigation. Liquidity remains comfortably above conventional thresholds even after this compression. The trend is worth tracking, since the quarterly swings suggest liquidity depends on timing of receivables and payables.

The reduction in accumulated deficit of roughly $249M over three quarters is substantial, though part of this movement appears tied to non-operating or one-time items given the earnings volatility noted in prior analysis. Equity expansion therefore reflects both retained profit and capital contributions, and the quality of that growth is not fully transparent from the balance sheet alone. Stock-based compensation remains a dilution consideration investors should track.